– Reinforcing strategic focus on chronic hepatitis delta and chronic hepatitis B clinical programs and antibody platform to target infectious diseases, autoimmune diseases, and oncology –– Reducing workforce by approximately 12% and consolidating geographic footprint –– Anticipate annual savings of at least $40 mill.
SAN FRANCISCO (BUSINESS WIRE) $VIR #JPM2024 Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, will present at the J.P. Morgan 2024 42nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET.A live webcas.
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD s The Liver Meeting® 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Company to present new data at AASLD from Phase 2 chronic hepatitis B and chronic hepatitis delta clinical trials –– Company expanding strategic focus to autoimmune diseases and immuno-oncology –– Jennifer Towne, Ph.D., appointed as Executive Vice President and Chief Scientific Officer, effective November 6, 2023.
Vir Biotechnology to Participate in the H C Wainwright 4th Annual Hepatitis B Virus (HBV) Conference tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.